Brainstorm Cell Therapeutics Inc.
BCLI
$1.22
$0.010.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.47M | 2.00M | 2.06M | 1.51M | 3.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.19M | 3.05M | 2.98M | 2.47M | 4.80M |
| Operating Income | -3.19M | -3.05M | -2.98M | -2.47M | -4.80M |
| Income Before Tax | -2.97M | -2.71M | -2.54M | -3.40M | -5.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.97M | -2.71M | -2.54M | -3.40M | -5.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.97M | -2.71M | -2.54M | -3.40M | -5.58M |
| EBIT | -3.19M | -3.05M | -2.98M | -2.47M | -4.80M |
| EBITDA | -3.14M | -2.99M | -2.92M | -2.41M | -4.74M |
| EPS Basic | -0.52 | -0.51 | -0.54 | -0.79 | -1.62 |
| Normalized Basic EPS | -0.33 | -0.32 | -0.33 | -0.49 | -1.01 |
| EPS Diluted | -0.52 | -0.51 | -0.54 | -0.79 | -1.62 |
| Normalized Diluted EPS | -0.33 | -0.32 | -0.33 | -0.49 | -1.01 |
| Average Basic Shares Outstanding | 5.71M | 5.31M | 4.75M | 4.32M | 3.44M |
| Average Diluted Shares Outstanding | 5.71M | 5.31M | 4.75M | 4.32M | 3.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |